Immunovant reports positive IMVT-1402 600 mg Phase 1 data: 74% IgG reduction, placebo-like albumin/LDL-C

Immunovant, Inc.

Four weekly 600 mg SC doses of IMVT-1402 reduced total IgG by mean 74%, similar to batoclimab's 76% at 680 mg.
No significant changes in serum albumin or LDL-C at Day 29 (p>0.05), consistent with placebo-like profile.
All doses well tolerated; only mild or moderate treatment-emergent adverse events observed.
Company expects ~80% steady-state IgG reduction with continued weekly 600 mg dosing after 6-8 weeks.
Immunovant says profile supports broad portfolio of first-in-class and best-in-class FcRn indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.